Stay up to date with the most recent announcements from the media

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Lifesciences

THE KEN

Apr 21, 2025

How a 14-member biotech spent just $10M on a product global pharma wants to lap up

One of the three companies globally to show cell therapy results for dry AMD, an eye disorder affecting nearly 200 million globally, Bengaluru’s Eyestem is also eyeing a disruptive price.

Lifesciences

Ophthamology Times

Apr 14, 2025

Eyestem releases positive results from phase 1 trial in patients with geographic atrophy

Eyecyte-RPE trial involved 9 patients with geographic atrophy, using three ascending dose levels of hiPSC-derived RPE cells. No serious adverse events were reported, and patients showed an average vision improvement of 14.9 letters on ETDRS tests.

Deep Tech

New Indian Express

Apr 10, 2025

Robots reimagined: Perceptyne making steely strides

Will robots take over the world? Well, while that is an age-old sci-fi cliffhanger, Perceptyne’s robots aren’t plotting domination — they’re rolling up their sleeves and getting to work.

Enterprise

Entrepreneur

Mar 29, 2025

Expertia AI Secures INR 20 Crore in Pre-Series A, Eyes 3x Revenue Growth in FY25

The newly raised funds will be directed toward product development and the expansion of Expertia's technology team.

No items found.

News

How a 14-member biotech spent just $10M on a product global pharma wants to lap up

Eyestem releases positive results from phase 1 trial in patients with geographic atrophy

Robots reimagined: Perceptyne making steely strides

Expertia AI Secures INR 20 Crore in Pre-Series A, Eyes 3x Revenue Growth in FY25